6
Participants
Start Date
May 31, 2005
Primary Completion Date
June 30, 2012
Bevacizumab 7.5 and TAC
Bevacizumab given intravenously at a dose of 7.5mg/kg every 3 weeks, followed by docetaxel, doxorubicin and cyclophosphamide (TAC).
Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)
placebo 7.5 will be adminitered intravenously every 3 weeks followed by TAC
Bevacizumab 15 and TAC
one dose of Bevacizumab (15 mg/kg) will be administered intravenously every 3 weeks followed by TAC.
Placebo 15 and TAC
one dose of placebo 15 will be administered intravenously every 3 weeks followed by TAC.
St. Vincent's University Hospital, Dublin
St. James's Hospital, Dublin
Northwest Georgia Oncology Centers, P.C., Marietta
Cancer Institute of Florida, P.A., Orlando
South Texas Oncology and Hematology, P.A., San Antonio
UCLA Medical Center, Los Angeles
Wilshire Oncology Medical Group, Inc., Pomona
Cross Cancer Institute, Edmonton
McGill University, Montreal
Collaborators (1)
Genentech, Inc.
INDUSTRY
Translational Oncology Research International
OTHER